

SciFinder[®]



Alcance de SciFinder

Química Física Biología Ingeniería Medicina Agricultura

SciFinder[®]

Materiales Microbios Farmacia **Textiles Tecnología Nuclear** Geología Y muchos más...

¿Qué es SciFinder?

- Herramienta de CAS (división de ACS) desarrollada para que científicos la aprovechen, en las áreas de ciencias de la vida y ciencias de los materiales
- Interfaz de fácil uso
- Navegación intuitiva

http://scifinder.cas.org



Bases de dados

- Acceso a 6 bases de datos :
 - CAPLUS Artículos, Patentes, Tesis, etc.
 - MEDLINE Informaciones de la Salud
 - REGISTRY Sustancias Químicas
 - CASREACT Reacciones Químicas
 - CHEMCATS Proveedores de Productos
 - CHEMLIST Listas Reglamentarias



Contenido

CAPlusSM

- >31M bibliographic records
- >10K journals covered
- Patents from 61 patent offices
- Updated daily (~3K daily)
- Links to almost 300 publishers and 3 patent offices
- Literature back to early 1800s
- Cited articles from 1997 onward

V OCILINGEL

CAS REGISTRYSM

- 49M small molecules
- >61M sequences
- Updated daily (>12K daily)
- Substances reported comprehensi vely in literature back to 1957
- Includes nomenclatur e, spectra, and properties (experimental and predicted)

CASREACT

- >18M single and multistep reactions
- Extracted from patents and journal articles
- Updated weekly (~30K weekly)
- Reactions
 back to 1840
- Reaction conditions starting in 2003

CHEMCATS

- >35M commercially available compounds
- >900 suppliers
- >1000 chemical catalogs
- Updated when new or revised catalogs are available
- Contact/ ordering information including quantity and pricing (when available)

CHEMLIST

- >248K inventoried / regulated substances
- >100

 inventories & regulated
 lists from
 1979 to
 present
- Updated weekly (~50 additions)
- Contains regulatory requirements for substances

MEDLINE

- produced by the U.S. National Library of Medicine (NLM)
- > 18 million references
- Biomedical literature from more than 4,780 journals and 70 countries
- covering literature from 1950 to the present
- Updated 5 times per week

Pantalla Principal - SciFinder On The Web

		0				
♦ SciFinder [®]	Explo	erences 😽 Explore 🛛 👗 Explore	plore eactions		TRANSFER	Saved Answer Sets Help KMP Alert Results History
Welcome Ana Daula Hesse	I Sign Out	,			4.70	SciPlanner Preferences
Welcome Ana Paula Hesse	a j Sigir Out					Cauced Answer Cata
Explore Reference	ces					Saved Answer Sets V
Research Topic	Research Topic 🚸				Search	No answer sets
Author Name		Examples: The effect of antibiotic residues on dains of	raducto			Import
Company Name		Photocyanation of aromatic compounds	louucis			Keen Me Docted Results 🏠
Document Identifier						
Journal						
Patent						
Tags						
	Publication Year(s) 🚸					
		Examples: 1995, 1995-1999, 1995-, -1995				
	Document Type(s) 🚸	Biography	Dissertation	Patent		
		Book	Editorial	Preprint		
		Clinical Trial	Historical	Report		
		Commentary	Journal	Review		
		Conference	Letter			
	(s) (s)					
	Language(3)		German	Polish		
				Coopich		
			- Japanese			
	Author Name 🚸					
		Last * First	Middle			
	Dáging	inicial con	ondionaa	de briegued		
	Pagina	i iniciai con	opciones	ue pusqueda	a, IISta	i de las
	U					

SciF búsquedas guardadas y "keep me post", etc.

Características del SciFinder

- La interfaz de búsqueda permite el uso de frases (limite hasta 5 palabras)
- Se pueden utilizar paréntesis para indicar los sinónimos de un concepto en particular.
- Se pueden utilizar "comillas" para encontrar conceptos exactos.
- Permite el uso de operadores Booleanos: OR, AND, WITH, NOT
- Emplea CAS RN en la búsqueda por tema
- SciFinder tiene un Thesaurus y un dicionario de sinónimos.



SciFinder Smarts

SciFinder[®]

Termino de Búsqueda	Terminos Asociados
Sinónimos incluyendo terminos controlados	- Paracetamol, Acetaminofen
Formas alternativas	 Freeze, froze, frozen, freezing Waste water, wastewater Antibacteriano, anti-bacteriano
Formas con plural irregular	 Woman, women Ox, oxen Mice, mouse, mousse Half life, half-life, halflife, halflives, half live, half lives, halflive, halflives
Abreviaciones de CAS	- Oxidation, Oxidn
Escritura Americana y Britanica	- Synthesize, synthesise
Regras de trucagem para recuperar palabras empezando por palabras de tronco comun	- Palabras terminadas en -tion con una raíz de por lo menos 5 letras son truncadas (depletion – deple?)- Palabras que contienen -able , -ed , -ing como sufijos son truncadas (solvable – solv?)- Palabras que contienen -e al final son truncadas (disease – diseas?)

Búsqueda – Explore References

♦ SciFinder [®]	Explor Refer	e Explore Explore Explore Reaction	ns		TELEPER	Saved Answer Sets KMP Alert Results	Help History
Welcome Ana Paula Hesse Sign Ou	t				Transie	SciPlanner	Preferences What's New
Explore References						Saved Answer Set	s 🚸
						No answer sets	
Research Topic Resea	irch Topic 😻	Examples:			Search	Import	
Author Name		The effect of antibiotic residues on dairy product					
Company Name		rnotocyunation or aromatic compounds				Keep Me Posted R	esults 🚸
Document Identifier						No profiles exist	
Journal							
Fatent							=
Tags							
Public	ation Year(s) 🚸						
		Examples: 1995, 1995-1999, 1995-, -1995					
Docum	nent Type(s) 🚸	Biography	Dissertation	Patent			
		Book	Editorial	Preprint			
		Clinical Trial	Historical	Report			
		Commentary	Journal	Review			
		Conference	Letter				
1				—			
Langu	lage(s) 🛷	Chinese	🖾 German	Polish			
		English	💷 Italian	Consist			
		Frencn	💷 Japanese	💷 Spanisn			
Autho	r Name 🚸		Indresar con	el témin	o de h	núsque	da
		Last * First Mide	ingrood off				
ידי ס 🔨	.]						
SCIFI	nder®						

Búsqueda – Explore References

					C
Publication Year(s) 🚸	Examples: <i>1995, 19</i>	95-1999, 1995-, -1995	7		
Document Type(s) 🚸	Biography		Dissertation	Patent	
	Book		Editorial	Preprint	
	🔲 Clinical Trial		Historical	Report	
	Commentary		Journal	Review	
	Conference		Letter		
Language(s) 🚸	Chinese		🔲 German	Polish	
	🔲 English		Italian	Russian	
	E French		Japanese	Spanish 🔲	
Author Name 🚸					
	Last *	First	Middle		
Company Name 🚸					
	Examples: Minnesota Mining an	d Manufacturing			
	DuPont	-			

SciFinder Campos para refinar ya en la página de búsqueda

Resultados – Explore References

♦ S	ciFinder [®] Explore Substances Legalore References	A STATE
Welcome	Ana Paula Hesse Sign Out IP Alert > Research Topic "acetaminophen and headache"	A LAN
Resea	arch Topic Candidates	
5 Topics	0 Selected	
Select A	NI Deselect All	
Select A	All Deselect All	
Select A	All Deselect All Research Topic Candidates	References
Select A	All Deselect All Research Topic Candidates 2 references were found containing "acetaminophen and headache" as entered.	References 2
Select A	NI Deselect All Research Topic Candidates 2 references were found containing "acetaminophen and headache" as entered. 695 references were found containing both of the concepts "acetaminophen" and "headache".	References 2 695
Select A	NI Deselect All Research Topic Candidates 2 references were found containing "acetaminophen and headache" as entered. 695 references were found containing both of the concepts "acetaminophen" and "headache". 113685 references were found containing either the concept "acetaminophen" or the concept "headache".	References 2 695 113685
Select A	Research Topic Candidates 2 references were found containing "acetaminophen and headache" as entered. 695 references were found containing both of the concepts "acetaminophen" and "headache". 113685 references were found containing either the concept "acetaminophen" or the concept "headache". 37069 references were found containing the concept "acetaminophen".	References 2 695 113685 37069
	Research Topic Candidates 2 references were found containing "acetaminophen and headache" as entered. 695 references were found containing both of the concepts "acetaminophen" and "headache". 113685 references were found containing either the concept "acetaminophen" or the concept "headache". 37069 references were found containing the concept "acetaminophen". 77311 references were found containing the concept "headache".	References 2 695 113685 37069 77311

Reference

SciFinder[®]

Eligir los "candidatos" de su interés para llegar a la de resultados. Después, hacer clic en GET REFERENCES

Resumen de Herramientas

En la página de resultados, usted puede utilizar las seguientes herramientas:

- Analizar
- Categorizar
- Refinar
- Guardar respuestas (completa o parcial)
- Keep me Posted (completo o parcial)
- Obtener Referencias, Substancias, Reacciones, Citas, Fuente Comercial, Información Regulatoria, etc.

♦ SciFinder[®]

Resumen del Documento

A SoiFindon®		Saved Answer Sets	Help
V SCIFILICIEI	0.00	KMP Alert Results	History
Welcome Ana Paula Hesse Sign Out	Kindette	SciPlanner	What's New
Add KMP Alert Research Topic "acetaminophen and headache" > references (695)	Contraction of the second		- maco nem
		Analaria	Defea
References & Get Substances & Get Reactions Get Related Colors Send to		Analysis	Kenne
605 Deferences 0 Selected	Save Brint Export	Analyze by: 🚸	
Select All Deselect All Soft by: Arcession Number V	1 2 3 4 5 6 35	Author Name	
	Diarlan = =		
1. Use of adapasing receptor agapter to modulate permashility of blood brain barrier to treat central persons guttern (CNC) disorders Ris #7-4	Display: =	Click bar to view only tho	se
By Bynoe, Margaret S.	e 1	references within the curr	rent
From PCT Int. Appl. (2012), WO 2012037457 A1 20120322. Language: English, Database: CAPLUS	~0 🚰 📘	answer set	0
The invention relates to a method of increasing blood brain barrier ("BBB") permeability in a subject. This method involves treatment of CNS disorders b the subject an agent or agents which activate both of the A1 and A2A adenosing recentors. Adenosing recentor activating agents of the invention	y administering to	прил к в	9
lexiscan, CGS-21680. Also disclosed is a method to decrease BBB permeability in a subject. This method includes administering to the subject an agen	t which inhibits or	Diener H C	6
blocks the A2A adenosine receptor signaling.			
		Faleck Herbert	6
2. Pharmaceutical composition containing acetaminophen, caffeine, chlorpheniramine maleate and artificial bezoar and its preparation Brull Text	1	Lister Biskerd B	
By Liu, Desheng	~0 👔	Lipton Richard B	0
The pharmaceutical compn. contains acetaminophen, caffeine, chlorpheniramine maleate and artificial bezoar at a mass ratio of 90~ 160:3~ 7:0.1	~ 0.6:5~ 10, and	Manning Donald C	6
optional filler, disintegrating agent and corrective . Filler is mannitol, dextrin, lactose, microcryst. cellulose and/or starch. Disintegrating agent is crossli	nked PVP, sodium		
nydroxymetnyl starch, low-substituted nydroxypropyl cellulose, crosslinked sodium CM-cellulose and/or alginate. Corrective is xylitol, lactose, mannitol, s The preprimethod comprises mixing acetaminophen, caffeine, chlorobeniramine maleat	ucrose, citric and.	Silberstein Stephen D	6
The prepris meanor comprises mixing accuminoprical, careine, enorphennamine maleucari			
\square 3. Runrenorphine 5, 10 and 20 µg/h transformal natch: a review of its use in the management of chronic non-malignant pain. B set Test	2	Evers S	5
By Plosker, Greg L.	99 	Haan Gunther	5
From Drugs (2011), 71(18), 2491-2509. Language: English. Database: CAPLUS	~0 💁		
Norspan) in the management of chron Hacor clic on of titulo dol docume	onto nara	llogar	2 2
primarily as a partial agonist at the mu	sino para	lieyai	aia
drug conces. throughout the 7-day dos		out por	
pagina del resumen y detailes, o		exi par	d
4. Tramadol hydrochloride/acetaminoph			
By Sawaddiruk, P. From Drugs of Today (2011), 47(10), 763-772. accesar a la pagina del editor			
Tramadol hydrochloride/acetaminophen is a compination drug concer granador hydrochloride or sing and acetaminophen ozo ing. The use of zor		VALEQUIZE	

Resumen del Documento

♦ SciFinder[®]

SciFinder [®]	Explore Reactions	THE REAL	Saved Answer Sets KMP Alert Results	Help History
Welcome Ana Paula Hesse Sign Out	Buprenorphine 5, 10 and 20 µg/	The second	SciPlanner	What's New
Reference Detail & Get Substances & Get Reactions Get Citing	Get Send to SciPlanner	1	Quick Links	
	Link Save	Print Export	· · · rags, o comments	
🦘 Return	•	Previous Next	Source	
3. Buprenorphine 5, 10 and 20 µg/h transdermal patch: a reverse by: Plosker, Greg L. This article reviews the pharmacol., therapeutic efficacy and tolerability profile of the 7 management of chronic non-malignant pain, with a focus on European labeling for the the mu opioid receptor. The transdermal formulation provides continuous delivery of be interval. The analgesic efficacy of transdermal buprenorphine in patients with osteoart have shown the formulation to be equiv. to sublingual buprenorphine, noninferior to pr combination tablets (when transdermal buprenorphine was used together with regulard Transdermal buprenorphine was significantly more effective than placebo in reducing Other clin. trials, including a randomized, double-blind, maintenance-of-analgesia stud chronic non-malignant pain of various causes. In general, serious adverse events with buprenorphine has a ceiling effect for respiratory depression, and the main risk is where transdermal buprenorphine was better tolerated than sublingual buprenorphine in a 7 opioids, persistence with transdermal buprenorphine therapy is difficult for many patier demonstrated good efficacy and tolerability in clin. trials in chronic non-malignant pain other persistent pain syndromes of at least moderate beneficial clin. implications, most notably the convenience of once-weekly administration making it an opioid of choice in these patients, and a useful therapeutic option overall	iew of its use in the management of chronic non-malignant pat- day lower-dose (5, 10 and 20 µg/h) buprenorphine transdermal patch (BuTrans, Nors, drug. Buprenorphine is a semi-synthetic opioid analgesic that acts primarily as a parti- buprenorphine, resulting in relatively consistent plasma drug concns. throughout the 7- thritis of the hip and/or knee has been demonstrated in several randomized controlled to rolonged-release tramadol tablets, noninferior to codeine plus paracetamol (acetaminop y scheduled oral paracetamol) and generally superior to a matching transdermal placed chronic low back pain of at least moderate severity in two randomized, double-blind, cr ly, have also demonstrated the analgesic efficacy of transdermal buprenorphine in patie transdermal buprenorphine are similar to those for other opioid analgesics. Transderm in it is combined with other CNS depressants. The most frequently reported adverse ev uth, nausea, vomiting, pruritus, erythema, application site pruritus and application site -wk, randomized, double-blind trial in patients with osteoarthritis pain. Nevertheless, a nts because of adverse events or other reasons. Thus, transdermal buprenorphine has the severity. It also has favorable pharmacodynamic and pharmacokinetic properties, whi on and no need for dosage adjustments in the elderly or those with compromised renal in the management of chronic non-malignant pain.	in pan) in the al agonist at day dosing trials, which hen) to patch. to so patch. to so patch. to so patch. to so patch. to so sover trials. ents with then al ents with reactions. to with other generally atients with th have function,	Drugs Volume71 Issue18 Pages2491-2509 Journal 2011 CODEN:DRUGAY ISSN:0012-6667 Company/Organiz Adis, a Wolters Kluwer Auckland, N. Z. Accession Number 2012:262941 CAPLUS Publisher	ation Business
Indexing			woiters Kluwer Health	
Pharmacology (Section1) 🐼			Language	
Citations	Detalles del documento,	inforr	nacion	es –

bibliográficas, etc.

CAS Full Text Options

SciFinder[®]



Hacer clic en Full Text para accesar el texto completo a través del CAS full text options®

Analizar

🔷 SciFinder®	Explore References Explore Substan	ces Acctions		The second se		Saved Answer Sets KMP Alert Results	Help History
Velcome Ana Paula Hesse Sign Out					interior	SciPlanner	Preferences What's New
Add KMP Alert Research Topic "aceta	minophen and headache" > reference	es (695)					What's New
References & Get	Get Reactions 🚰 Get 🔻 💥 Tools	s ▼ Send to SciPlanner				Analysis	Refine
695 References 0 Selected				Save Print	Export	Analyze by: 🕢	
Select All Deselect All Sort by: Acce	ssion Number 💌 🦊		Answers per Page [20]	1 2 3 4 5 6	. 35 🕨	Author Name	•
 1. Use of adenosine receptor agor By Bynoe, Margaret S. From PCT Int. Appl. (2012), WO 201203 The invention relates to a methor the subject an agent or agents lexiscan, CGS-21680. Also discl blocks the A2A adenosine recept 2. Pharmaceutical composition co By Liu, Desheng 	iists to modulate permeability of blood- 7457 A1 20120322. Language: English, Datal od of increasing blood brain barrier ("BBI ; which activate both of the A1 and A2 osed is a method to decrease BBB perm tor signaling. mtaining acetaminophen, caffeine, chlor	brain barrier to treat central nervous system (abase: CAPLUS 3B") permeability in a subject. This method invo 2A adenosine receptors. Adenosine receptor a neability in a subject. This method includes ad pheniramine maleate and artificial bezoar and	CNS) disorders I Full Text plyes treatment of CNS disorders by activating agents of the invention in ministering to the subject an agent of its preparation Full Text	Display: administering to nclude AMP-579, which inhibits or	~~ 💼 📰	Citck var to view only thou references within the curr answer set Lipton R B Diener H C Faleck Herbert Lipton Richard B	se rent 9 6 6 6
From Faming Zhuanli Shenqing (2012), (The pharmaceutical compn. cor optional filler, disintegrating age hydroxymethyl starch, low-subsi The prepn. method comprises r	IN 102370664 A 20120314. Language: Chine Itains acetaminophen, caffeine, chlorp ant and corrective . Filler is mannitol, de tituted hydroxypropyl cellulose, crosslink nixing acetaminophen, caffeine, chlorp	ese, Database: CAPLUS pheniramine maleate and artificial bezoar at a lextrin, lactose, microcryst. cellulose and/or star ced sodium CM-cellulose and/or alginate. Corre pheniramine maleat	mass ratio of 90~ 160:3~ 7:0.1~ rch. Disintegrating agent is crosslink ctive is xylitol, lactose, mannitol, suc	0.6:5~ 10, and ked PVP, sodium crose, citric acid.	~0 😰	Manning Donald C Silberstein Stephen D	6
3. Buprenorphine 5, 10 and 20 µg By Plosker, Greg L. From Drugs (2011), 71(18), 2491-2509. This article reviews the pharma Norspan) in the management of primarily as a partial agonist at the design of the pharma the p	/h transdermal patch: a review of its us Language: English, Database: CAPLUS col., therapeutic efficacy and tolerability f chronic non-malignant pain, with a foc the mu opioid receptor. The transdermal with a site and the angle of the site o	se in the management of chronic non-malignan y profile of the 7-day lower-dose (5, 10 and 20 cus on European labeling for the drug. Buprence al formulation provides continuous delivery of bu	t pain Pull Text Uµg/h) buprenorphine transdermal prphine is a semi-synthetic opioid an iprenorphine, resulting in relatively co	patch (BuTrans, Ialgesic that acts onsistent plasma	~0 ≦	Haag Gunther Lewis Donald W	5
A. Tramadol hydrochloride/acetar By Sawaddiruk, P. From Drugs of Today (2011), 47(10), 76 Tramadol hydrochloride/acetan	ninophen combination for the relief of : 3-772. Language: English, Database: CAPLL ninophen is a combination drug conta.	En la página analizar la lis	de los resu ta por dife	ultado rente:	os e s.	s posíb	ole

Analizar





Analizar por nombre de autor, CAS RN, nombre de instituición, tipo de documento, revista, idioma, SciFinde

Refinar

SciFinder [®] Explore References Explore Substances Explore Reactions	1. Y.	Saved Answer Sets KMP Alert Results SciPlanner	Help History Preferences
Mercome Ana Paula Hesse Sign Out Add KMP Alert Research Topic "acetaminophen and headache" > references (695) > Buprenorphine 5, 10 and 20 µg/	STATISTICS .		What's New
References & Get Substances & Get Reactions & Get Related & K Tools & Send to SciPlanner	(Analysis	Refine
695 References 0 Selected	Save Print Export	Refine by: 🕖	
Select All Deselect All Sort by: Accession Number 💌 🦊 Answers per Page [20]	1 2 3 4 5 6 35 🕨	Research Topic	
	Display: 🗖 💻 🔳	O Author Name	
1. Use of adenosine receptor agonists to modulate permeability of blood-brain barrier to treat central nervous system (CNS) disorders 🗈 Full Text	.	Company Name	
By Bynoe, Margaret S. From PCT Int. Appl. (2012), WO 2012022457 A1 20120222, Lippergrave English, Dotobace, CARLUS	~0 🚯	O Document Type	
The invention relates to a method of increasing blood brain barrier ("BBB") permeability in a subject. This method involves treatment of CNS disorders by a	administering to	Publication Year	
the subject an agent or agents which activate both of the A1 and A2A adenosine receptors. Adenosine receptor activating agents of the invention inc	clude AMP-579,	Canguage	
lexiscan, CGS-21680. Also disclosed is a method to decrease BBB permeability in a subject. This method includes administering to the subject an agent w blocks the A2A adenosine receptor signaling.	/hich inhibits or	O Database	
2. Pharmaceutical composition containing acetaminophen, caffeine, chlorpheniramine maleate and artificial bezoar and its preparation Brull Text By Liu, Desheng From Faming Zhuanli Shenqing (2012), CN 102370664 A 20120314. Language: Chinese, Database: CAPLUS The pharmaceutical compn. contains acetaminophen, caffeine, chlorpheniramine maleate and artificial bezoar at a mass ratio of 90~ 160:3~ 7:0.1~ (optional filler, disintegrating agent and corrective . Filler is mannitol, dextrin, lactose, microcryst. cellulose and/or starch. Disintegrating agent is crosslinked hydroxymethyl starch, low-substituted hydroxypropyl cellulose, crosslinked sodium CM-cellulose and/or alginate. Corrective is xylitol, lactose, mannitol, sucr The prepn. method comprises mixing acetaminophen, caffeine, chlorpheniramine maleat	ی ۵.6:5~ 10, and ed PVP, sodium rose, citric acid.	Research Topic	isidues on
3. Buprenorphine 5, 10 and 20 µg/h transdermal patch: a review of its use in the management of chronic non-malignant pain B Full Text By Plosker, Greg L. From Drugs (2011), 71(18), 2491-2509. Language: English, Database: CAPLUS This article reviews the pharmacol., therapeutic efficacy and tolerability profile of the 7-day lower-dose (5, 10 and 20 µg/h) buprenorphine transdermal p Norspan) in the management of chronic non-malignant pain, with a focus on European labeling for the drug. Buprenorphine is a semi-synthetic opioid ana primarily as a partial agonist at the mu opioid receptor. The drug concns. throughout the 7-day dosing interval. The ana	~0 😭 vatch (BuTrans, Ilgesic that acts	Photocyanation of aroma compounds Refine	tic
En la pagina de resultados	es posib	ole refin	ar
By Sawaddiruk, P. From Drugs of Today (2011), 47(10), 763-772. Language: English, Dat	netros.		

Tramadol hydrochloride/acetaminophen is a combination orug contq. tramadol hydrochloride 37.5 mg and acetaminophen 325 mg. The use of 25% less tramadol in

Refinar



Analysis	Refine	
Refine by: 🚸		
 Research Topic Author Name Company Name Document Type Publication Year Language Database 		
Research Topic		

Refinar por tópico de búsqueda, nombre de autor, nombre de instituición, tipo de documento, año de publicación, idioma o base de dados.



SciFinder[®]

Structure Editor	×
T Image: Constraint of the constrai	Bortcut Keys Shortcut Keys Shortcut Keys Get substances that match your query using: Exact search Substructure search
• • •	Scale 100 Cancelar

Plug-in para dibujo de la fórmula estructural



La fórmula estructural el término de búsqueda. Mas abajo hay algunas herramientas de refino.



Oppciones para refinar y direccionar la lista de resultados.

Resultados – Explore Substances



Resultados – Explore Substances



Desde los resultados es posible accesar:

- 1. Detalles de la Substancia
- 2. Documentos sobre a Substancia
- 3. Reacciones de la substancia
- 4. Proveedores
- 5. Información Regulatória
- 6. Espectros y Propiedades Experimentales

Detalles de la Substancia



Detalles de la Substancia

Predicted Properties: Biological Chemical Density Lipinski and Related Spectra Structure-related Thermal

Biological Properties	Value	Condition	Note
Bioconcentration Factor	69.3	pH 1 Temp: 25 °C	(85)
Bioconcentration Factor	69.3	pH 2 Temp: 25 °C	(85)
Bioconcentration Factor	69.3	pH 3 Temp: 25 °C	(85)
Bioconcentration Factor	69.3	pH 4 Temp: 25 °C	(85)
Bioconcentration Factor	69.3	pH 5 Temp: 25 °C	(85)
Bioconcentration Factor	69.2	pH 6 Temp: 25 °C	(85)
Bioconcentration Factor	69.0	pH 7 Temp: 25 °C	(85)
Bioconcentration Factor	66.6	pH 8 Temp: 25 °C	(85)
Bioconcentration Factor	49.6	pH 9 Temp: 25 °C	(85)
Bioconcentration Factor	13.9	pH 10 Temp: 25 °C	(85)
Chemical Properties	Value	Condition	Note
Кос	723	pH 1 Temp: 25 °C	(85)
Кос	723	pH 2 Temp: 25 °C	(85)
Кос	723	pH 3 Temp: 25 °C	(85)
Кос	723	pH 4 Temp: 25 °C	(85)
Кос	723	pH 5 Temp: 25 °C	(85)
Кос	723	pH 6 Temp: 25 °C	(85)
Кос	720	pH 7 Temp: 25 °C	(85)
Кос	695	pH 8 Temp: 25 °C	(85)
Кос	517	pH 9 Temp: 25 °C	(85)
Кос	146	pH 10 Te 75 00	(05)
logD	2.72	pH1Ten Propiedades	Estimadas
logD	2.72	pH 2 Ten	
Joon .	רד ר	nH 2 Tomp: 25.00	(05)

Detalles de la Substancia

Experimental Properties: Biological Chemical Density Electrical Lipinski and Related Optical and Scattering Spectra Structure-related Thermal

Biological Properties	Value	Condition	Note
ADME (Absorption, Distribution, Metabolism, Excretion)	See full text		(2) CAS
LC50	See full text	1 of 3	(29) CAS
Median Lethal Dose(LD50)	2400 mg/kg	Organism: rat Route: oral	(32) CAS
Minimum Inhibitory Concentration	See full text		(76) CAS
Chemical Properties	Value	Condition	Note
Acid/Base Dissociation Constant (Ka/Kb)	See full text	1 of 3	(1) CAS
Dissociation Constant	See full text		(21) CAS
logP	See full text	1 of 2	(30) CAS
Molecular Electric Dipole Moment	See full text		(77) CAS
Partition Coefficient	See full text	1 of 12	(78) CAS
Potential of Electrode Reaction	See full text	1 of 4	(25) CAS
Solubility	See full text		(80) CAS
Density Properties	Value	Condition	Note
Density	1.22 g/cm3	Temp: 4 °C	(4) CAS
Density	1.0954 g/cm3	Temp: 98.7 °C	(5) NLM
Electrical Properties	Value	Condition	Note
Dielectric Constant	See full text		(20) CAS
Lipinski and Related Properties	Value	Condition	Note
logP	See full text	1 of 2	(30) CAS
Optical and Scattering Properties	Value		
Refractive Index	1.9224	Propledades Experimentales	
Refractive Index	1.6224	Wavien: 569.5 nm; remp: 99 °C	
Defendition Index.	1 (110	Merdan, 500 Dame Terrar 20.00	(0) 010

Expectros RMN, IR, etc

♦ SciFinder[®]



Acceso a diferentes tipos de espectros de la substancia.

Reacciones



Reacciones

♦ SciFinder[®]



Dibujar la reacción

Reacciones

Explore Reactions



Reacciones - Resultados

Welcome Ana Paula Hesse Sign Out	reactions (61)	SciPianner Preierences What's New
Reactions Get References Tools V Send to SciPlanner		Analysis Refine
61 Reactions 0 Selected	Seve Drink Expert	Milaryze by:
Select All Deselect All Sort by: Relevance	Answers per Page [15] 1 2 3 4 5 🕨	Catalyst
1. View Reaction Detail Link Similar Reactions Single Step Hover over any structure for more options.	Display: 💾 🕼 🔇 🧕	Click bar to view only those reactions within the current answer set RuCl ₃ 9 MeN ⁺ ((CH2)7Me)3 •Cl ⁻ 7
$ \longrightarrow 100\% $		1034805-97-4 2 1343-93-7 2 851956-06-4 2
-		
 ▼ Overview Steps/Stages 1.1 R:H₂O₂, C:1034805-97-4, C:MeN⁺((CH₂)₇Me)₃ •Cl⁻, S:H₂O, S:<i>i</i>-BuCMe 	Notes 3, 7 h, 60°C green chemistry - catalyst, green chemistry - solvent, selective oxidation, multiphase	851956-08-6 2 <i>t</i> -BuOOH 2
Enlar	página de resultados. la lista de r	eacciones

En la pagina de resultados, la lista de reacciones que atienden a los criterios de la búsqueda y herramientas para analizar o refinar.

Herramientas – Páginas de Resultados



riFinder®

En las páginas de resultados hay diferentes herramientas tales como Keep Me Posted, Get Substances, Get Reactions, Artículos Citados, Artículos Citantes, Acceso a Texto Completo, Combinar lista de resultados, etc

Herramientas – Páginas de Resultados



En las páginas de resultados es possible Guardar, Imprimir o Exportar la lista completa de resultados, o aquellos seleccionados. Tambien es posible definir cómo mostrar la lista.

Alerta: El limite de downloads por sesión es 5.000 títulos.





O SciPlanner es una nueva herramienta disponible en el SciFinder que permite crear y administrar proyectos de síntesis orgánica, asociando sustancias, reacciones y bibliografías.

Un video esta disponible con un ejemplo de su utilización, en el link:

http://www.youtube.com/watch?v=T73Ojm3-3Ts

http://www.cas.org/etrain/scifinder/sciplanner.html



Herramientas en la Web





María Teresa Cabrera materesa.cabrea@itmsgroup.net Mónica Arriagada Delgado monica.arriagada@itmsgroup.net

